The latest price target for Atossa Therapeutics (NASDAQ:ATOS) was reported by Rodman & Renshaw on July 7, 2026. The analyst firm set a price target for $12.00 expecting ATOS to rise to within 12 months (a possible 404.20% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Atossa Therapeutics (NASDAQ:ATOS) was provided by Rodman & Renshaw, and Atossa Therapeutics initiated their buy rating.

There is no last upgrade for Atossa Therapeutics

There is no last downgrade for Atossa Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atossa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atossa Therapeutics was filed on July 7, 2026 so you should expect the next rating to be made available sometime around July 7, 2027.

While ratings are subjective and will change, the latest Atossa Therapeutics (ATOS) rating was a initiated with a price target of $0.00 to $12.00. The current price Atossa Therapeutics (ATOS) is trading at is $2.38, which is within the analyst’s predicted range.